Aelix Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MVA.HTI / Aelix Therap
AELIX-003, NCT04364035 / 2018-002125-30: Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

Completed
2a
50
Europe
ChAdOx1.HTI, MVA.HTI, GS-9620, Vesatolimod, Placebo, Placebo Oral Tablet, N/H
Aelix Therapeutics, Gilead Sciences
HIV/AIDS
10/22
12/22
2018-002125-30: A study to evaluate how safe MVA.HTI and ChAdOx1.HTI vaccines with vesatolimod are in participants with early treated HIV-1 infection. Un estudio para evaluar la seguridad de las vacunas MVA.HTI y ChAdOx1.HTI con vesatolimod en sujetos participantes con infección por VIH-1 tratados de forma precoz.

Not yet recruiting
2
57
Europe
MVA.HTI, ChAdOx1.HTI, Vesatolimod, MVA.HTI, ChAdOx1.HTI, GS-9620, Suspension for injection, Film-coated tablet
AELIX Therapeutics, AELIX Therapeutics
Human immunodeficiency virus type 1 Virus de inmunodeficiencia humana tipo 1, Human immunodeficiency virus (HIV) Virus de inmunodeficiencia humana (VIH), Diseases [C] - Virus Diseases [C02]
 
 
NCT05208125: A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

Completed
1
30
Europe
ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS)., Normal saline solution
IrsiCaixa, José Moltó Marhuenda, PhD, MD, Beatriz Mothe Pujadas PhD,MD, Susana Benet Garrabé, PhD,MD, Lucía Bailón Álvarez, MD
HIV Infection
03/22
12/23
ChAdOx1.HTI / Aelix Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MVA.HTI / Aelix Therap
AELIX-003, NCT04364035 / 2018-002125-30: Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

Completed
2a
50
Europe
ChAdOx1.HTI, MVA.HTI, GS-9620, Vesatolimod, Placebo, Placebo Oral Tablet, N/H
Aelix Therapeutics, Gilead Sciences
HIV/AIDS
10/22
12/22
2018-002125-30: A study to evaluate how safe MVA.HTI and ChAdOx1.HTI vaccines with vesatolimod are in participants with early treated HIV-1 infection. Un estudio para evaluar la seguridad de las vacunas MVA.HTI y ChAdOx1.HTI con vesatolimod en sujetos participantes con infección por VIH-1 tratados de forma precoz.

Not yet recruiting
2
57
Europe
MVA.HTI, ChAdOx1.HTI, Vesatolimod, MVA.HTI, ChAdOx1.HTI, GS-9620, Suspension for injection, Film-coated tablet
AELIX Therapeutics, AELIX Therapeutics
Human immunodeficiency virus type 1 Virus de inmunodeficiencia humana tipo 1, Human immunodeficiency virus (HIV) Virus de inmunodeficiencia humana (VIH), Diseases [C] - Virus Diseases [C02]
 
 
NCT05208125: A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

Completed
1
30
Europe
ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS)., Normal saline solution
IrsiCaixa, José Moltó Marhuenda, PhD, MD, Beatriz Mothe Pujadas PhD,MD, Susana Benet Garrabé, PhD,MD, Lucía Bailón Álvarez, MD
HIV Infection
03/22
12/23
ChAdOx1.HTI / Aelix Therap
No trials found

Download Options